Autolus Therapeutics (NASDAQ:AUTL) Shares Gap Up - Here's What Happened

Autolus Therapeutics plc (NASDAQ:AUTL - Get Free Report)'s share price gapped up prior to trading on Wednesday . The stock had previously closed at $2.03, but opened at $2.11. Autolus Therapeutics shares last traded at $2.04, with a volume of 118,877 shares traded.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on AUTL. The Goldman Sachs Group upgraded shares of Autolus Therapeutics from a "neutral" rating to a "buy" rating and upped their price objective for the stock from $7.00 to $7.60 in a research report on Monday, November 18th. Redburn Atlantic raised shares of Autolus Therapeutics from a "neutral" rating to a "buy" rating and set a $13.00 target price for the company in a research note on Friday, November 15th. Finally, Needham & Company LLC reissued a "buy" rating and set a $10.00 target price on shares of Autolus Therapeutics in a research note on Monday, January 13th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, Autolus Therapeutics presently has a consensus rating of "Buy" and a consensus price target of $10.40.

Autolus Therapeutics Stock Performance

The company has a market cap of $518.88 million, a PE ratio of -1.61 and a beta of 2.02. The firm's 50 day moving average is $2.24 and its 200-day moving average is $3.21.

Institutional Trading of Autolus Therapeutics

Large investors have recently bought and sold shares of the business. Hennion & Walsh Asset Management Inc. purchased a new stake in Autolus Therapeutics during the 4th quarter valued at about $611,000. Wellington Management Group LLP grew its stake in Autolus Therapeutics by 35.4% during the 3rd quarter. Wellington Management Group LLP now owns 24,220,226 shares of the company's stock valued at $87,919,000 after acquiring an additional 6,330,392 shares in the last quarter. FMR LLC grew its stake in Autolus Therapeutics by 44.6% during the 3rd quarter. FMR LLC now owns 17,773,873 shares of the company's stock valued at $64,519,000 after acquiring an additional 5,478,706 shares in the last quarter. Erste Asset Management GmbH purchased a new stake in shares of Autolus Therapeutics in the 3rd quarter valued at approximately $708,000. Finally, GSA Capital Partners LLP purchased a new stake in shares of Autolus Therapeutics in the 3rd quarter valued at approximately $1,082,000. Hedge funds and other institutional investors own 72.83% of the company's stock.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.